Regeneron and Bayer's Eylea has been racking up sales that have consistently topped analyst expectations since its U.S. rollout in late 2011. Now, new data may help it potentially top them in a market Novartis and Roche got to first.
On " 60 Minutes," Dr. Peter Bach and Leonard Saltz deliver some sound bites that might get the general public talking--and politicians, too.
Drugs such as Roche/Genentech's Avastin (bevacizumab) boost the survival odds of some ovarian cancer patients but not others. Researchers from The University of Manchester in the U.K. and colleagues believe they've developed a new blood test that can help find patients for whom the drug works best.
After promising last month to fast track its review of Roche's Avastin in cervical cancer, the FDA has come back with a positive verdict--a full two months before its deadline. The agency approved the blockbuster drug to be used in combination with chemotherapy in women with advanced cervical cancer.
Last week, France made its move to knock the Novartis eye drug Lucentis out of drug coverage and move its cheaper cousin Avastin into its place. Now, Novartis and its Lucentis partner Roche are fighting back.
One of two men from Turkey that federal authorities accused of smuggling counterfeit cancer drugs to the U.S. labeled as gifts or documents has admitted he is guilty.
Last week, it was priority review for cervical cancer. This week, it's the fast track for difficult-to-treat ovarian cancer.
Last week, it was priority review for cervical cancer. This week, it's the fast track for difficult-to-treat ovarian cancer. That's the record for Roche's Avastin, which is now up for quick FDA approval of two new indications.
Roche's cancer blockbuster Avastin has yet another shot at boosting sales. The FDA put Avastin up for priority review in cervical cancer, with a decision date of Oct. 24.
When it comes to expanding Avastin into new cancer territories, Roche has a win-some, lose-some record. Now, Roche is closer to adding cervical cancer to its arsenal of indications in the U.S.